FG-M108
Phase 3Small molecule
FG-M108 is one of 40 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1FG-M108
FFutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Active Comparator
ModernaPreclinical
Secretin-Ferring
FerringPreclinical
Sulfonylureas
Eli LillyPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Claudin 18.21 trial
An Open-Label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-M108 Injection in Combination With FG-B901 Injection in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors
Not yet recruiting·FFutureGen Biopharmaceutical (Beijing) Co., Ltd·Preclinical·NCT07704866·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FG-M108. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details